Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
Identifieur interne : 000A83 ( Ncbi/Merge ); précédent : 000A82; suivant : 000A84Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
Auteurs : Aimee Coscarart [États-Unis] ; Julianna Martel [États-Unis] ; Michael P. Lee [États-Unis] ; Alun R. Wang [États-Unis]Source :
- Journal of cutaneous pathology [ 1600-0560 ] ; 2020.
Abstract
Pembrolizumab, an anti-programmed cell death-1 (PD-1) antibody preparation, has been shown to induce various dermatologic adverse events which may present with delayed onset or even after discontinuation of therapy. We report a 78-year-old female patient with a stage II lung adenocarcinoma treated with pembrolizumab, who developed lichenoid eruptions and multiple cutaneous plaque/nodular eruptions as pseudoepitheliomatous hyperplasia, during and up to 2 months after discontinuation of pembrolizumab therapy. Multiple skin biopsies revealed epidermal hyperplasia with hyperkeratosis, hypergranulosis, diffuse to patchy lichenoid lymphocyte infiltrate with scattered eosinophils and neutrophils, confluent to scant dyskeratosis of the lower epidermis, minimal to overt invagination, and cystic proliferation of squamous epithelium to papillomatosis with hypergranulosis and keratosis. Overall, multiple patterns were present with similarities to lichenoid drug eruption, lichen planus, early invasive squamous cell carcinoma, early keratoacanthoma, and verruca. However, the findings ultimately supported a diagnosis of hypertrophic lichen planus. All the lesions resolved with oral prednisone, hydroxychloroquine, and topical triamcinolone acetonide ointment 0.1%. In summary, our case shows that pembrolizumab can induce lichenoid eruption with pseudoepitheliomatous hyperplasia, and these lesions can clinically and pathologically mimic early invasive squamous cell carcinomas or keratoacanthomas.
DOI: 10.1111/cup.13587
PubMed: 31589773
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000029
- to stream PubMed, to step Curation: 000029
- to stream PubMed, to step Checkpoint: 000003
Links to Exploration step
pubmed:31589773Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.</title><author><name sortKey="Coscarart, Aimee" sort="Coscarart, Aimee" uniqKey="Coscarart A" first="Aimee" last="Coscarart">Aimee Coscarart</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Martel, Julianna" sort="Martel, Julianna" uniqKey="Martel J" first="Julianna" last="Martel">Julianna Martel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Lee, Michael P" sort="Lee, Michael P" uniqKey="Lee M" first="Michael P" last="Lee">Michael P. Lee</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Wang, Alun R" sort="Wang, Alun R" uniqKey="Wang A" first="Alun R" last="Wang">Alun R. Wang</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:31589773</idno><idno type="pmid">31589773</idno><idno type="doi">10.1111/cup.13587</idno><idno type="wicri:Area/PubMed/Corpus">000029</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000029</idno><idno type="wicri:Area/PubMed/Curation">000029</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000029</idno><idno type="wicri:Area/PubMed/Checkpoint">000003</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000003</idno><idno type="wicri:Area/Ncbi/Merge">000A83</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.</title><author><name sortKey="Coscarart, Aimee" sort="Coscarart, Aimee" uniqKey="Coscarart A" first="Aimee" last="Coscarart">Aimee Coscarart</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Martel, Julianna" sort="Martel, Julianna" uniqKey="Martel J" first="Julianna" last="Martel">Julianna Martel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Lee, Michael P" sort="Lee, Michael P" uniqKey="Lee M" first="Michael P" last="Lee">Michael P. Lee</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author><author><name sortKey="Wang, Alun R" sort="Wang, Alun R" uniqKey="Wang A" first="Alun R" last="Wang">Alun R. Wang</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Louisiane</region></placeName><wicri:cityArea>Department of Pathology and Dermatology, Tulane University, New Orleans</wicri:cityArea></affiliation></author></analytic><series><title level="j">Journal of cutaneous pathology</title><idno type="eISSN">1600-0560</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pembrolizumab, an anti-programmed cell death-1 (PD-1) antibody preparation, has been shown to induce various dermatologic adverse events which may present with delayed onset or even after discontinuation of therapy. We report a 78-year-old female patient with a stage II lung adenocarcinoma treated with pembrolizumab, who developed lichenoid eruptions and multiple cutaneous plaque/nodular eruptions as pseudoepitheliomatous hyperplasia, during and up to 2 months after discontinuation of pembrolizumab therapy. Multiple skin biopsies revealed epidermal hyperplasia with hyperkeratosis, hypergranulosis, diffuse to patchy lichenoid lymphocyte infiltrate with scattered eosinophils and neutrophils, confluent to scant dyskeratosis of the lower epidermis, minimal to overt invagination, and cystic proliferation of squamous epithelium to papillomatosis with hypergranulosis and keratosis. Overall, multiple patterns were present with similarities to lichenoid drug eruption, lichen planus, early invasive squamous cell carcinoma, early keratoacanthoma, and verruca. However, the findings ultimately supported a diagnosis of hypertrophic lichen planus. All the lesions resolved with oral prednisone, hydroxychloroquine, and topical triamcinolone acetonide ointment 0.1%. In summary, our case shows that pembrolizumab can induce lichenoid eruption with pseudoepitheliomatous hyperplasia, and these lesions can clinically and pathologically mimic early invasive squamous cell carcinomas or keratoacanthomas.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">31589773</PMID><DateRevised><Year>2020</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0560</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of cutaneous pathology</Title><ISOAbbreviation>J. Cutan. Pathol.</ISOAbbreviation></Journal><ArticleTitle>Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.</ArticleTitle><Pagination><MedlinePgn>275-279</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cup.13587</ELocationID><Abstract><AbstractText>Pembrolizumab, an anti-programmed cell death-1 (PD-1) antibody preparation, has been shown to induce various dermatologic adverse events which may present with delayed onset or even after discontinuation of therapy. We report a 78-year-old female patient with a stage II lung adenocarcinoma treated with pembrolizumab, who developed lichenoid eruptions and multiple cutaneous plaque/nodular eruptions as pseudoepitheliomatous hyperplasia, during and up to 2 months after discontinuation of pembrolizumab therapy. Multiple skin biopsies revealed epidermal hyperplasia with hyperkeratosis, hypergranulosis, diffuse to patchy lichenoid lymphocyte infiltrate with scattered eosinophils and neutrophils, confluent to scant dyskeratosis of the lower epidermis, minimal to overt invagination, and cystic proliferation of squamous epithelium to papillomatosis with hypergranulosis and keratosis. Overall, multiple patterns were present with similarities to lichenoid drug eruption, lichen planus, early invasive squamous cell carcinoma, early keratoacanthoma, and verruca. However, the findings ultimately supported a diagnosis of hypertrophic lichen planus. All the lesions resolved with oral prednisone, hydroxychloroquine, and topical triamcinolone acetonide ointment 0.1%. In summary, our case shows that pembrolizumab can induce lichenoid eruption with pseudoepitheliomatous hyperplasia, and these lesions can clinically and pathologically mimic early invasive squamous cell carcinomas or keratoacanthomas.</AbstractText><CopyrightInformation>© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coscarart</LastName><ForeName>Aimee</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martel</LastName><ForeName>Julianna</ForeName><Initials>J</Initials><Identifier Source="ORCID">https://orcid.org/0000-0001-5854-9459</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Alun R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Pathology and Dermatology, Tulane University, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cutan Pathol</MedlineTA><NlmUniqueID>0425124</NlmUniqueID><ISSNLinking>0303-6987</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PD-1</Keyword><Keyword MajorTopicYN="N">hypertrophic lichen planus</Keyword><Keyword MajorTopicYN="N">pembrolizumab</Keyword><Keyword MajorTopicYN="N">pseudoepitheliomatous hyperplasia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>09</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31589773</ArticleId><ArticleId IdType="doi">10.1111/cup.13587</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.</Citation></Reference><Reference><Citation>Wang M, Ma X, Guo L, et al. Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. Drug Des Devel Ther. 2017;11:2851-2860.</Citation></Reference><Reference><Citation>Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2013;69(3):e121-e128.</Citation></Reference><Reference><Citation>Lederhandler MH, Ho A, Brinster N, et al. Severe oral mucositis: a rare adverse event of pembrolizumab. J Drugs Dermatol. 2018;17(7):807-809.</Citation></Reference><Reference><Citation>Joseph RW, Cappel M, Goedjen B, et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res. 2015;3(1):18-22.</Citation></Reference><Reference><Citation>Siegel J, Mariam T, Damsky W, et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol. 2018;79(6):1081-1088.</Citation></Reference><Reference><Citation>Kunimasa K, Isei T, Nakamura H, et al. Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction. Invest New Drugs. 2018;36(6):1138-1142.</Citation></Reference><Reference><Citation>Chaudhari S, Leon A, Levin E, Neuhaus I, Liao W. Case report of multiple keratoacanthomas and squamous cell carcinomas in a patient receiving pembrolizumab. J Drugs Dermatol. 2017;16(5):513-515.</Citation></Reference><Reference><Citation>Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME. Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatol. 2017;153(7):694-697.</Citation></Reference><Reference><Citation>Kwiek B, Schwartz RA. Keratoacanthoma (KA): an update and review. J Am Acad Dermatol. 2016;74(6):1220-1233.</Citation></Reference><Reference><Citation>Fleich T, Chiticariu E, Huber M, Hohl D. Keratoacanthoma: a distinct entity? Exp Dermatol. 2016;25(2):85-91.</Citation></Reference><Reference><Citation>Antonov NK, Nair KG, Halasz CL. Transient eruptive keratoacanthomas associated with nivolumab. JAAD Case Rep. 2019;5(4):342-345.</Citation></Reference><Reference><Citation>Zayour M, Lazova R. Pseudoepitheliomatous hyperplasia: a review. Am J Dermatopathol. 2011;33(2):112-116.</Citation></Reference><Reference><Citation>Levandoski KA, Nazarian RM, Asgari MM. Hypertrophic lichen planus mimicking squamous cell carcinoma: the importance of clinicopathologic correlation. J Am Acad Dermatol. 2017;3(2):151-154.</Citation></Reference><Reference><Citation>Price A, Miller JH, Junkins-Hopkins JM. Pseudocarcinomatous hyperplasia in anaplastic large cell lymphoma, a mimicker of poorly differentiated squamous cell carcinoma: report of a case and review of the literature. J Cutan Pathol. 2015;42(11):863-869.</Citation></Reference><Reference><Citation>Ansari M, Azmoodeh Ardalan F, Najafi M, et al. Primary cutaneous lymphoma-associated pseudoepitheliomatous hyperplasia masquerading as squamous cell carcinoma in a young adult. Acta Med Iran. 2015;53(12):785-788.</Citation></Reference><Reference><Citation>Abu-Eid R, Landini G. Morphometrical differences between pseudo-epitheliomatous hyperplasia in granular cell tumours and squamous cell carcinomas. Histopathology. 2006;48(4):407-416.</Citation></Reference><Reference><Citation>Perniciaro C, Randle HW, Perry HO. Hypertrophic discoid lupus erythematosus resembling squamous cell carcinoma. Dermatol Surg. 1995;21(3):255-257.</Citation></Reference><Reference><Citation>Alagheband M, Engineer L. Lithium and halogenoderma. Arch Dermatol. 2000;136(1):126-127.</Citation></Reference><Reference><Citation>Cardis MA, Jiang H, Strauss J, Gulley JL, Brownell I. Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report. BMC Cancer. 2019;19(1):539.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Louisiane</li></region></list><tree><country name="États-Unis"><region name="Louisiane"><name sortKey="Coscarart, Aimee" sort="Coscarart, Aimee" uniqKey="Coscarart A" first="Aimee" last="Coscarart">Aimee Coscarart</name></region><name sortKey="Lee, Michael P" sort="Lee, Michael P" uniqKey="Lee M" first="Michael P" last="Lee">Michael P. Lee</name><name sortKey="Martel, Julianna" sort="Martel, Julianna" uniqKey="Martel J" first="Julianna" last="Martel">Julianna Martel</name><name sortKey="Wang, Alun R" sort="Wang, Alun R" uniqKey="Wang A" first="Alun R" last="Wang">Alun R. Wang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A83 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000A83 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:31589773
|texte= Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:31589773" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |